ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer




ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

Webinar on Wednesday, September 1st @ 10am ET/4pm CET


Cambridge, MA (U.S.) and Lyon (France), August 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today it will host a key opinion leader webinar on its lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, on Wednesday, September 1, 2021 at 10:00am Eastern Time. The webinar will feature a presentation by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University.

Dr. Hidalgo will discuss ERYTECH’s lead product candidate eryaspase, L-asparaginase encapsulated inside donor-derived red blood cells, in the ongoing Phase 3 TRYbeCA-1 trial which has completed enrollment of 512 second-line metastatic pancreatic cancer patients at approximately 90 clinical sites in Europe and the United States. The TRYbeCA-1 trial is expected to read out final results in Q4 2021. Additionally, Dr. Hidalgo will discuss the medical need and treatment options in second-line pancreatic cancer and speak on his hopes and expectations for the data read out in Q4 2021.

Dr. Noel will then discuss the view of evaluating eryaspase beyond the second-line setting. Currently, Dr. Noel is conducting in the United States an investigator sponsored Phase 1 dose-escalation trial (rESPECT) with eryaspase in combination with standard chemotherapy as part of first-line treatment for locally advanced and metastatic pancreatic cancer. Dr. Noel will share his current experience of treating patients with eryaspase in combination with chemotherapy in the first-line setting.

To register for the event, please click here.

Manuel Hidalgo, M.D., Ph.D., is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital “12 de Octubre” in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to serve as Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. Dr. Hidalgo also served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the use of Avatar mouse models for cancer research and recently contributed to the development and Federal Drug Administration (FDA) approval of nab-paclitaxel for pancreatic cancer treatment. Dr. Hidalgo’s current research focuses on strategies for personalized medicine and immunotherapy in pancreatic cancer. Dr. Hidalgo also serves on the Board of Directors for Bristol Myers Squibb (BMS).

Marcus S. Noel, M.D., is a medical oncologist who specializes in the treatment of gastrointestinal cancers. At Georgetown Lombardi Comprehensive Cancer Center, Dr. Noel is Associate Professor of Medicine and Co-Director, Clinical Research Management Office, both within the Division of Hematology and Oncology, Department of Medicine. His research efforts focus on novel drug development for pancreatic cancer. He obtained a Bachelor of Arts degree in biology from Case Western Reserve University and his medical degree from Rutgers Medical School formerly Robert Wood Johnson Medical School. Dr. Noel completed his internal medicine residency and medical oncology fellowship at the University of Rochester Medical Center in 2013. He was recently an assistant professor of medicine at the Wilmot Cancer Institute in Rochester New York.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        
For more information, please visit www.erytech.com        

CONTACTS

ERYTECH                     
Eric Soyer
CFO & COO
LifeSci Advisors, LLC
Corey Davis, Ph.D.
Investor relations

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
investors@erytech.com

+1 (212) 915 2577
cdavis@lifesciadvisors.com

+33 1 44 71 94 94
erytech@newcap.eu

Attachment